Home » Topics » BioWorld Science

BioWorld Science
RSS

Preliminary phase I/II data for BMS-986148 monotherapy and combination with nivolumab

Nov. 15, 2019

Gilead presents phase II results for selgantolimod in patients with chronic HBV

Nov. 15, 2019

Hoth Therapeutics initiates preclinical testing of topical aprepitant

Nov. 15, 2019

First patient dosed in phase Ib/IIa proof-of-concept study of BRII-179

Nov. 15, 2019

Cerveau Technologies starts Japanese phase I study of [18F]MK-6240

Nov. 15, 2019

Arthrosi Therapeutics presents preclinical and phase I results for AR-882

Nov. 15, 2019

Sansheng's clinical trial application for HIF-117 capsules cleared in China

Nov. 15, 2019

Nouscom initiates phase I study of NOUS-209 in microsatellite unstable solid tumors

Nov. 15, 2019

Aged gut microbiota transplants show benefits in young mice

Nov. 15, 2019

Merck & Co.'s MK-5890 shows acceptable safety profile and early antitumor activity

Nov. 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...